Abstracts tagged "systemic lupus erythematosus (SLE) and vaccines"

Abstract Number: 951 • 2019 ACR/ARP Annual Meeting
Avoidable Acute Care Use for Vaccine-Preventable Illnesses Among Medicaid Beneficiaries with Lupus: Demographic and Healthcare Utilization Differences
Candace Feldman¹, Chang Xu ¹ and Karen Costenbader ¹, ¹Brigham and Women's Hospital, Boston, MA
Background/Purpose: Nearly 25% of patients with SLE are hospitalized each year often for outcomes that may have been avoided if patients had received sustained, high…
Abstract Number: 2606 • 2017 ACR/ARHP Annual Meeting
Pneumococcal Vaccination in Patients with Systemic Lupus Erythematosus: A Multicenter Placebo-Controlled Randomized Double-Blind Study
Sophie Grabar¹, Matthieu Groh², Mathilde Bahuaud³, Nathalie Costedoat-Chalumeau⁴, Veronique Le Guern⁵, Renato Fior⁶, Boris Bienvenu⁷, eric hachulla⁸, Mohamed Hamidou⁹, Jean Sibilia¹⁰, Alexis Mathian¹¹, Thomas Hanslik¹², Loïc Guillevin for the French Vasculitis Study Group¹³, Frédéric Batteux³ and Odile Launay¹⁴, ¹Université Paris Descartes, Sorbonne Paris Cité AP-HP, Unité de Biostatistique et Epidémiologie, Groupe Hospitalier Cochin Broca Hôtel-Dieu, Paris, France; INSERM, UPMC Université Paris 06, Institut Pierre Louis d’épidémiologie et de Santé Publique (IP, Paris, France, ²National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ³Université Paris Descartes, Sorbonne Paris Cité AP-HP, Département d’Immunologie Biologique, Groupe Hospitalier Cochin Broca Hôtel-Dieu, Paris, France, Paris, France, ⁴Service de médecine interne Pôle médecine, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares de l’île de France, Paris, France, ⁵Department of Internal Medicine, Department of Internal Medicine, Cochin University Hospital, Paris, France, ⁶Université Paris-Sud, AP-HP, Service de Médecine Interne et Immunologie Clinique, Hôpital Antoine Béclère, Clamart, France, Clamant, France, ⁷Internal Medicine, Hôpital de la côte de Nacre, Caen, France, ⁸chru lille hospital, lille, France, ⁹Medecine Interne, CHU Hôtel Dieu, Nantes, France, ¹⁰Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹¹Université Pierre et Marie Curie, Sorbonne Paris Cité AP-HP, Service de Médecine Interne 2, Centre de Référence National pour le Lupus et le Syndrome des Antiphospholipides, institut E3M, Paris, France, Paris, France, ¹²Université Versailles Saint-Quentin-en-Yvelines, APHP, Service de Médecine Interne, Hôpital Ambroise Paré, Boulogne-Billancourt, France, Boulogne-Billancourt, France, ¹³Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France, ¹⁴Université Paris Descartes, Sorbonne Paris Cité AP-HP, Groupe Hospitalier Cochin Broca Hôtel-Dieu, Fédération d'Infectiologie, Paris, France; Inserm, F-CRIN I-REIVAC., Paris, France
Background/Purpose: Invasive pneumococcal disease and respiratory tract infections are both frequent and severe in patients with systemic lupus erythematosus (SLE). This study aimed to compare…
Abstract Number: 748 • 2016 ACR/ARHP Annual Meeting
A Phase 4, Multicenter, Randomized, Open-Label Study to Evaluate the Effect of Belimumab on Vaccine Responses in Patients with Systemic Lupus Erythematosus
Winn Chatham¹, Aneureka Chadha², James Fettiplace³, Christi Kleoudis⁴, Damon Bass⁵, David Roth⁵ and David Gordon⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²Austin Regional Clinic, Austin, TX, ³GSK, Uxbridge, Middlesex, United Kingdom, ⁴Parexel, Raleigh-Durham, NC, ⁵GSK, Philadelphia, PA
Background/Purpose: Intravenous (IV) belimumab 10 mg/kg is approved in patients with active, autoantibody-positive systemic lupus erythematosus (SLE) as add-on to standard SLE therapy (SoC). This…
Abstract Number: 2447 • 2016 ACR/ARHP Annual Meeting
Does a History of Abnormal Pap Smear or Preceeding HPV Infection Affect Humoral Immune Response to Quadrivalent Human Papilloma Virus (qHPV) Vaccine in Women with Systemic Lupus Erythematosus (SLE)
J. Patricia Dhar^1,2, Lynnette Essenmacher³, Renee Dhar⁴, Ardella Magee⁵, Joel Ager⁶ and Robert Sokol⁷, ¹Internal Medicine, Wayne State University School of Medicine, Detroit, MI, ²Internal Medicine, Central Michigan University College of Medicine, Saginaw, MI, ³Wayne State University School of Medicine, Detroit, MI, ⁴CMED medical student, Central Michigan University College of Medicine, Mt. Pleasant, MI, ⁵Clinical and Translational Research Center, Wayne State University, Detroit, MI, ⁶Family Medicine, Wayne State University School of Medicine, Detroit, MI, ⁷Department of Obstetrics & Gynecology, Wayne State University School of Medicine, Detroit, MI
Background/Purpose: Cervical neoplasia is increased in women with SLE. HPV types 16 & 18 account for 70% of cervical cancer. Natural HPV cervical infection generates…
Abstract Number: 2781 • 2016 ACR/ARHP Annual Meeting
Immunization with ApoB100 Peptide Vaccine Reduces Atherosclerosis Development in a Mouse Model of Systemic Lupus Erythematosus
Ingrid Yao-Mattisson, Maria Wigren, Gunilla Nordin Fredrikson and Jan Nilsson, Lund University, Malmö, Sweden
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by impaired self-tolerance causing damage to multiple organs including the cardiovascular system. Current therapies do…
Abstract Number: 1766 • 2015 ACR/ARHP Annual Meeting
HPV Vaccination of Nzbxw/F1 Mice
Maria Teresa Arango¹, Lucija Tomljenovic², Miri Blank¹ and Yehuda Shoenfeld³, ¹Sheba Medical Center, Zabludowicz Center for Autoimmune Diseases, affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel, ²University of British Columbia, Neural Dynamics Research Group, Department of Ophthalmology and Visual Sciences, Vancouver, BC, Canada, ³Sheba Medical Center, Zabludowicz Center for Autoimmune Diseases, affiliated to affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel
Background/Purpose: Human-papilloma virus vaccine (HPVv) is currently used worldwide. Still this vaccine has been linked to a variety of neurological and autoimmune manifestations. For instance,…
Abstract Number: 1839 • 2015 ACR/ARHP Annual Meeting
Safety and Immunogenicity of Quadrivalent Human Papilloma Virus (qHPV) Vaccine (Gardasil®) in Systemic Lupus Erythematous (SLE), Phase I Trial Completion
J. Patricia Dhar^1,2, Lynnette Essenmacher³, Renee Dhar⁴, Ardella Magee⁵, Joel Ager⁶ and Robert Sokol⁷, ¹Internal Medicine, Wayne State University, Detroit, MI, ²Internal Medicine, Central Michigan University College of Medicine, Saginaw, MI, ³Wayne State University School of Medicine, Detroit, MI, ⁴CMED medical student, Central Michigan University College of Medicine, Mt. Pleasant, MI, ⁵Clinical and Translational Research Center, Wayne State University, Detroit, MI, ⁶Family Medicine, Wayne State University School of Medicine, Detroit, MI, ⁷Department of Obstetrics & Gynecology, Wayne State University School of Medicine, Detroit, MI
Background/Purpose: Women with SLE are at increased risk for HPV-related cervical disease. The qHPV vaccine immunizes and is protective against HPV types that cause the…
Abstract Number: 718 • 2014 ACR/ARHP Annual Meeting
Safety of Gardasil® Vaccine in Systemic Lupus Erythematosu, Trial Update
J. Patricia Dhar^1,2, Lynnette Essenmacher³, Renee Dhar^4,5, Ardella Magee⁶, Harpreet Sagar², Malini Venkatram⁷ and Robert Sokol⁸, ¹Internal Medicine, Central Michigan University College of Medicine, Saginaw, MI, ²Internal Medicine/Rheumatology, Wayne State University, Detroit, MI, ³Wayne State University, Detroit, MI, ⁴Clinical Research Center, Wayne State University, Detroit, MI, ⁵CMED medical student,, Central Michigan University College of Medicine, Mount Pleasant, MI, ⁶Clinical Research Center, Wayne State University, Detroit, MI, ⁷Division of Rheumatology, Wayne State University, Detroit, MI, ⁸Obstetrics and Gynecology, Wayne State University, Detroit, MI
Background/Purpose: Cervical neoplasia is increased in women with SLE presumably due to cervical infection with oncogenic Human Papillomavirus (HPV) types which persist in an immunosuppressed…
Abstract Number: 2835 • 2013 ACR/ARHP Annual Meeting
Safety Of Gardasil® Vaccine In Systemic Lupus Erythematosus
J. Patricia Dhar¹, Lynnette Essenmacher², Renee Dhar³, Ardella Magee⁴, Joel Ager⁵, Malini Venkatram¹, Harpreet Sagar¹ and Robert Sokol⁶, ¹Internal Medicine/Rheumatology, Wayne State University, Detroit, MI, ²Wayne State University, Detroit, MI, ³Department of Clinical and Translational Research, Wayne State University, Detroit, MI, ⁴Clinical Research Center, Wayne State University, Detroit, MI, ⁵Family Medicine Department, Wayne State University, Detroit, MI, ⁶Obstetrics and Gynecology, Wayne State University, Detroit, MI
Background/Purpose: Cervical neoplasia is increased in women with SLE presumably due to cervical infection with oncogenic Human Papillomavirus (HPV) types which persist in an immunosuppressed…
Abstract Number: 1564 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Influenza Vaccination Is Strongly Decreased In Systemic Lupus Erythematosus: A Meta-Analysis Of Literature Data
Laurent Arnaud¹, Alexis Mathian², Hervé Devilliers³, Du Boutin-LE Thi Huong⁴, Ahlem Chaib⁴, Fleur Cohen-Aubart⁴, Julien Haroche¹, Miguel Hié⁴, Makoto Miyara⁴ and Zahir Amoura⁴, ¹Internal Medicine, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ²Internal medicine 2, French National Reference Center for Systemic Lupus and Antiphospholipid Syndrome, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ³Internal medicine and systemic disease unit, Dijon University Hospital, Dijon, France, ⁴Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France
Background/Purpose: Several studies suggest that the efficacy of influenza vaccination may be decreased in systemic lupus erythematosus (SLE). We performed a meta-analysis to assess systematically…
Abstract Number: 1565 • 2013 ACR/ARHP Annual Meeting
RNA-Sequencing Confirms Clinical Safety Of Herpes Zoster Vaccine
Christopher J. Lessard^1,2, Indra Adrianto³, Joel M. Guthridge⁴, John A. Ice³, Graham B. Wiley³, Stuart B. Glenn³, Judith A. James^1,2, Joan T. Merrill¹, Patrick M. Gaffney¹, Courtney G. Montgomery³, Kathy L. Sivils^1,5 and Eliza Chakravarty³, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: SLE patients have increased risk of Herpes Zoster (HZ). A live-attenuated vaccine is available for healthy persons > 50 years old, but its safety…
Abstract Number: 572 • 2013 ACR/ARHP Annual Meeting
Immunization With Hepatitis B Vaccine Accelerates SLE-Like Disease In An Animal Model
Nancy Agmon-Levin¹, María Teresa Arango², Shaye Kivity³, Aviva Katzav⁴, Boris Gilburd⁵, Miri Blank^6,7, Juan-Manuel Anaya⁸, Gisele Zandman-Goddard⁹, Joab Chapman¹⁰ and Yehuda Shoenfeld¹¹, ¹The Zabludowicz Center for Autoimmune Diseases, Tel-Hashomer, Israel, ²Doctoral Program in Biomedical Sciences Universidad del Rosario, Bogota, Colombia;Center for Autimmune Diseases Research – CREA, Universidad del Rosario,, Bogota, Colombia, ³Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, affliated to Sackler Faculty of Medicine, Tel-Aviv University Israel, Tel-Aviv, Israel, ⁴Department of. Neurology and Sagol Neuroscience Center, Sheba Medical Center,Tel-Hashomer, Ramat Gan, Israel, ⁵The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel, ⁶Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, affiliated to Sackler Medical School, Tel Aviv University, Ramat Gan, Israel, ⁷Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, affiliated to Sackler Faculty of Medicine,Tel Aviv University, Tel-Aviv, Tel-Aviv, Israel, ⁸School of Medicine and Health Sciences, Universidad del Rosario. Center for Autoimmune Diseases Research (CREA), Bogotá, Colombia, ⁹Internal Medicine C, Wolfson Medical Center;Sackler Faculty of Medicine, Tel-Aviv University, Holon, Israel, ¹⁰Department of. Neurology and Sagol Neuroscience Center, Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel, ¹¹The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Ramat Gan, Israel
Background/Purpose: Hepatitis-B vaccine (HBVv) was proven to be successful and cost effective in preventing HBV infection and associated liver disease. However, in recent years concerns…
Abstract Number: 1819 • 2012 ACR/ARHP Annual Meeting
Predictors of Pneumococcal Vaccination in Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus
Anna Gramling¹, Kaleb Michaud², Harlan Sayles³, Frederick Wolfe⁴ and Michelene Hearth-Holmes⁵, ¹Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE, ³Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁴National Data Bank for Rheumatic Diseases, Wichita, KS, ⁵Internal Medicine/Rheumatology Division, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are at high risk for serious infection, including those caused by Streptococcus pneumoniae. Administration…
Abstract Number: 1408 • 2012 ACR/ARHP Annual Meeting
Monitoring Patients with Systemic Lupus Erythematosus in Clinical Practice: Have You Already Checked the Vaccination Status in Your Patients?
Olga Malysheva, Jean-Philipp Ivanov, Sybille Arnold and Christoph G. Baerwald, Rheumatology, University Hospital, Leipzig, Germany
Background/Purpose: : Infection is one of the main causes of morbidity and increased mortality in patients with systemic lupus erythematodes (SLE). Information about vaccination history and…
Abstract Number: 627 • 2012 ACR/ARHP Annual Meeting
Zostavax Vaccine Is Safe in Lupus Patients with Low Disease Activity
Eliza F. Chakarvarty¹, Joel M. Guthridge², Joan T. Merrill³, Abigail Cogman², Tiny Powe¹, Virginia C. Roberts⁴ and Judith A. James⁵, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, CA, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis Immunology, OMRF, Oklahoma City, OK, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: The Zostavax vaccine was FDA approved in 2006 for the prevention of herpes zoster in healthy adults over age 50. Because it is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].